We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Healthcare Partners with Pfizer to Develop Companion Diagnostics

By LabMedica International staff writers
Posted on 11 Feb 2014
Siemens Healthcare Diagnostics, of Siemens Healthcare (Erlangen, Germany), has entered into a collaboration agreement with the global, research-based pharmaceutical company Pfizer (New York City, NY, USA), to design, develop, and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline. Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies and, potentially, eventual global commercialization with Pfizer products.

The Siemens Clinical Laboratory (SCL), a high-complexity testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under this partnership. The collaboration will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care settings to help enable diagnostics development.

"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, senior vice president and Worldwide Head of Development Operations at Pfizer. “This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs." Companion diagnostic tests are clinical tests linked to a specific drug or therapy, intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.

"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," said Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare; "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and together shape the future of diagnostic medicine."

Related Links:

Siemens Healthcare
Pfizer



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Celiac Disease Test
Anti-Gliadin IgG ELISA

Latest Industry News

Quanterix Completes Acquisition of Akoya Biosciences
11 Feb 2014  |   Industry

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
11 Feb 2014  |   Industry

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
11 Feb 2014  |   Industry



PURITAN MEDICAL